biocardia.com (BCDA) - Company Sales Volume

The scientific determination of BioCardia, Inc. (BCDA) management in developing cell therapy defines the business's strategic direction. The company's sales performance reflects this process, where the current parameter equals 0.00. The issuer's success is based on the safety of the CardiAMP system, while financial flexibility is maintained by delegating trials to international CROs, thereby minimizing operational risks.

BioCardia, Inc (BCDA) Revenue and Sales Volume: for the period 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for BioCardia (BCDA)

- share price and expert price forecast:

Price Performance Chart BioCardia Inc|BCDA - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization BioCardia, Inc.|BCDA - Enterprise Value

- issuer book value statistics:

Net Assets per Share BioCardia|BCDA - Book Capitalization|Market Capitalization to Book Value Ratio biocardia.com|BCDA - Cumulative Company Assets

- debt and solvency information:

- earnings and market multiples details:

BCDA - Net Profit|Expected Profit BioCardia, Inc.|BCDA - P/E Multiple|Projected Price to Earnings biocardia.com|BCDA - PEG Multiple|Enterprise Value to Operating Income Before Depreciation BioCardia, Inc.|BCDA - Operating profit EBITDA|Net earnings per share (EPS TTM) BioCardia|BCDA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months biocardia.com|BCDA - Earnings growth in current year|Expected net earnings per share growth next year BioCardia, Inc.

- company sales and revenue statistics:

BCDA - Revenue and Sales Volume|Projected Sales Volume BioCardia Inc|BCDA - Price-to-Revenue Ratio|Forward Price to Sales BioCardia, Inc.

Comprehensive company analysis:BioCardia Inc BCDA

BioCardia, Inc. (BCDA) implementation of ESG principles and bioethics in cell therapy requires stable funding, making the company's sales profile a key indicator of operational resilience. This metric captures actual cash inflows from sales, excluding accounting adjustments, allowing investors to distinguish systemic business growth from artificial revenue inflation occurring alongside declining margins and frozen capital.

Key competitors